Inspire Investing LLC Sells 8,725 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Inspire Investing LLC trimmed its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 21.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,633 shares of the company’s stock after selling 8,725 shares during the period. Inspire Investing LLC owned 0.06% of Pulse Biosciences worth $365,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares during the last quarter. Griffin Asset Management Inc. boosted its holdings in shares of Pulse Biosciences by 15.7% in the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after buying an additional 40,700 shares in the last quarter. Westside Investment Management Inc. grew its holdings in Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock worth $712,000 after purchasing an additional 31,440 shares during the last quarter. Bank of New York Mellon Corp increased its position in Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Friday.

Pulse Biosciences Stock Down 4.6 %

Shares of PLSE stock opened at $17.87 on Friday. Pulse Biosciences, Inc. has a 52-week low of $3.78 and a 52-week high of $22.69. The stock has a market cap of $986.87 million, a PE ratio of -22.06 and a beta of 1.75. The business has a 50-day simple moving average of $17.63 and a 200-day simple moving average of $12.63.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.